Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?

The optimal time for enzymatic AGAL activity measurement in migalastat-treated patients appears to be 24 h after the last migalastat intake. Since migalastat is a competitive inhibitor of AGAL, enzymatic AGAL activity measurements should be better performed from PBMCs to reduce migalastat-mediated interferences.

Authors

Institutions

Publication Details

Journal
BioDrugs
Published
2024-09-30
DOI
https://doi.org/10.1007/s40259-024-00678-x
Citations
2
Primary Topic
Lysosomal Storage Disorders Research
Type
article
Field-Weighted Citation Impact
0.65
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?

Malte Lenders, Elise Raphaela Menke, Eva Brand
2 citations
BioDrugs
Lysosomal Storage Disorders Research
0.65
article

Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?

Malte Lenders, Elise Raphaela Menke, Eva Brand
article en
2 citations

Abstract

The optimal time for enzymatic AGAL activity measurement in migalastat-treated patients appears to be 24 h after the last migalastat intake. Since migalastat is a competitive inhibitor of AGAL, enzymatic AGAL activity measurements should be better performed from PBMCs to reduce migalastat-mediated interferences.

BioDrugsVol. 38(6)
University Hospital Münster (DE)
Zero hunger
Openalex Percentile: Top 29%
Lysosomal Storage Disorders Research
0.65
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test? — Malte Lenders, Elise Raphaela Menke, et al. · BioDrugs (2024) | TGRS Research Map | TGRS